Sequence: LLIILRRRIRKQAHAHSK
splice-switching oligonucleotide
| Experiment Id | EXP000770 |
|---|---|
| Paper | Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, |
| Peptide | pVEC |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 5–10 μM |
| Rna Concentration | 500 nM |
| Mixing Ratio | CPP:ON 10:1 |
| Formulation Format | Non-covalent CPP–oligonucleotide complexes |
| Formulation Components | pVEC + splice-switching oligonucleotide ± pyrenebutyrate / chloroquine |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa; pLuc705 HeLa |
| Animal Model | |
| Administration Route | Cell incubation |
| Output Type | Splice-switching (luciferase induction) |
| Output Value | Strong effect only for R9 (enhanced by pyrenebutyrate + chloroquine) |
| Output Units | |
| Output Notes | Mechanistic study of uptake vs endocytosis; pyrenebutyrate enhances R9-mediated delivery |
| Toxicity Notes | TP10 shows cytotoxicity at low μM |
| Curation Notes |